These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Protein and polypeptide growth factors--T lymphocyte growth factor and interleukins]. Suzuki R; Kumagai K Nihon Rinsho; 1986 Jan; 44(1):42-7. PubMed ID: 2421027 [No Abstract] [Full Text] [Related]
4. [Physiological interferons and their role in the body. I. Biological activities of interferons]. Błach-Olszewska Z Postepy Hig Med Dosw; 1988; 42(3):260-95. PubMed ID: 3150039 [No Abstract] [Full Text] [Related]
6. [Cytokines and monoclonal antibodies. Immunologic approaches to tumor therapy]. Pfreundschuh M Fortschr Med; 1986 Dec; 104(47-48):973-6. PubMed ID: 2434398 [No Abstract] [Full Text] [Related]
7. Pathogenesis of rheumatoid arthritis. Kolarz G Acta Med Austriaca; 1988; 15(5):128-30. PubMed ID: 2464266 [TBL] [Abstract][Full Text] [Related]
8. [Inflammation and production of monokines. Human defense tissue response--pre-inflammatory response and interstitial cells]. Kyogoku M; Sawai T; Mori S Nihon Rinsho; 1987 May; 45(5):939-53. PubMed ID: 2442438 [No Abstract] [Full Text] [Related]
9. Potentiating effect of granulocyte-macrophage colony-stimulating factor on interleukin-1-induced thymocyte proliferation: evidence for an interleukin-2 and tumor necrosis factor-independent pathway. Herbelin A; Machavoine F; Dy M Lymphokine Res; 1990; 9(2):155-65. PubMed ID: 2187117 [TBL] [Abstract][Full Text] [Related]
10. Cell surface glycoproteins involved in the stimulation of interleukin 1-dependent interleukin 2 production by a subline of EL4 thymoma cells. I. Functional characterization by monoclonal antibodies. MacDonald HR; Lees RK; Bron C J Immunol; 1985 Dec; 135(6):3944-50. PubMed ID: 2415592 [TBL] [Abstract][Full Text] [Related]
11. [Interleukins as modulators of the immune system]. Röllinghoff M Ric Clin Lab; 1984; 14 Suppl 2():15-20. PubMed ID: 6241743 [No Abstract] [Full Text] [Related]
12. The interleukin 2 receptor and its physiology. Implications for combatting autoimmune diseases and transplant rejections. Diamantstein T Behring Inst Mitt; 1987 Jun; (81):73-87. PubMed ID: 3115248 [No Abstract] [Full Text] [Related]
13. Immunotherapy with lymphokine combinations. Mulé JJ; Rosenberg SA Important Adv Oncol; 1989; ():99-126. PubMed ID: 2468602 [No Abstract] [Full Text] [Related]
15. Biological response modifiers: the new immunotherapy. Foon KA Cancer Res; 1989 Apr; 49(7):1621-39. PubMed ID: 2466558 [No Abstract] [Full Text] [Related]
16. [Influences of the products of immune response on the functions of nervous and endocrine systems]. Su ZC Sheng Li Ke Xue Jin Zhan; 1992 Oct; 23(4):327-31. PubMed ID: 1284571 [No Abstract] [Full Text] [Related]
18. [Regulation of the immune response mediated by cellular interactions. Its relation to anti-tumor immunity]. Hajos SE Rev Argent Microbiol; 1987; 19(2):81-90. PubMed ID: 3332380 [No Abstract] [Full Text] [Related]
19. T cell receptor triggering induces responsiveness to interleukin 1 and interleukin 2 but does not lead to T cell proliferation. Meuer SC; Meyer zum Büschenfelde KH J Immunol; 1986 Jun; 136(11):4106-12. PubMed ID: 3084655 [TBL] [Abstract][Full Text] [Related]
20. [Biological response modifiers and cancer treatment]. Urushizaki I Gan No Rinsho; 1989 Jan; Spec No():25-33. PubMed ID: 2464707 [No Abstract] [Full Text] [Related] [Next] [New Search]